Biopharma companies wanting to treat rare diseases are increasingly pressed to be invested in gene therapy.
Novartis and Roche have recognized this with their...
The U.S. opioid crisis breathed new life into clinical development of the nerve-growth factor (NGF) inhibitors tanezumab and fasinumab. The drug class had been nearly...
Audentes Therapeutics is trying to show Sarepta isn't the only game in town when it comes to DMD. The collaboration with Nationwide's Children Hospital...
SAN FRANCISCO — Developing new medicines isn't a resource-efficient endeavor.
Estimates vary, but most molecules selected to begin clinical development won't end up on pharmacy...
Wednesday's settlement follows last month's conviction of five former Insys executives, including the company's founder John Kapoor, for their involvement in bribing physicians to...
The Securities and Exchange Commission filings that Spark released Monday confirm what became apparent when the FTC announced it was subjecting the Roche buyout...
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...
Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...
